Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer: experimental drug added to standard treatment

NCT ID NCT04702880

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an experimental drug called BMS-986012 to standard chemotherapy and immunotherapy works better for people newly diagnosed with extensive-stage small cell lung cancer. Researchers want to see if this combination is safe and can help patients live longer without their cancer getting worse. The trial involves 120 participants who will receive either the standard treatment alone or the standard treatment plus the new drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution

    Cincinnati, Ohio, 45267, United States

  • Local Institution

    Dallas, Texas, 75390, United States

  • Local Institution - 0001

    Malvern, Victoria, 3144, Australia

  • Local Institution - 0002

    Durham, North Carolina, 27710, United States

  • Local Institution - 0003

    Westmead, New South Wales, 2145, Australia

  • Local Institution - 0004

    Murdoch, Western Australia, 6150, Australia

  • Local Institution - 0005

    Majadahonda, 28222, Spain

  • Local Institution - 0006

    Málaga, 29010, Spain

  • Local Institution - 0007

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Local Institution - 0012

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0021

    Madrid, 28041, Spain

  • Local Institution - 0022

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0023

    Greenslopes, Queensland, 4120, Australia

  • Local Institution - 0029

    Rozzano, 20089, Italy

  • Local Institution - 0030

    Peschiera del Garda, 37019, Italy

  • Local Institution - 0031

    Pisa, 56124, Italy

  • Local Institution - 0034

    Ghent, 9000, Belgium

  • Local Institution - 0036

    Athens, 11527, Greece

  • Local Institution - 0038

    Athens, 185 47, Greece

  • Local Institution - 0039

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Local Institution - 0040

    Groningen, 9700RB, Netherlands

  • Local Institution - 0041

    Craiova, 200542, Romania

  • Local Institution - 0042

    Cluj-Napoca, 400015, Romania

  • Local Institution - 0043

    Bucharest, 022328, Romania

  • Local Institution - 0045

    Heraklion, Irakleío, 715 00, Greece

  • Local Institution - 0048

    Lodz, 93-338, Poland

  • Local Institution - 0049

    Gdansk, 80-214, Poland

  • Local Institution - 0050

    Liège, 4000, Belgium

  • Local Institution - 0051

    Charleroi, Hainaut, 6060, Belgium

  • Local Institution - 0060

    Cincinnati, Ohio, 45267, United States

  • Local Institution - 0064

    Brampton, Ontario, L6R 3J7, Canada

  • Local Institution - 0066

    Arnhem, 6815 AD, Netherlands

  • Local Institution - 0067

    Cleveland, Ohio, 44106-1716, United States

  • Local Institution - 0069

    Takatsuki, Osaka, 5698686, Japan

  • Local Institution - 0070

    Ōsaka-sayama, Osaka, 589-8511, Japan

  • Local Institution - 0073

    Sendai, Miyagi, 980-0873, Japan

  • Local Institution - 0075

    Birmingham, Alabama, 35249, United States

  • Local Institution - 0077

    Ina-machi, Saitama, 362-0806, Japan

  • Local Institution - 0081

    Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER